INTELLIGENT BIO SOLUTIONS INC
For the period ended Dec 31, 2024. Filed Feb 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2024 · Filed Feb 13, 2025
INBS$2.25-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months Ended December 31, | ||||
|---|---|---|---|---|
| 2024 · 2023 | ||||
| Cash Flows from Operating Activities | ||||
| Net loss | $(4,951,596) | $(4,408,807) | ||
| Adjustments to reconcile net loss to cash used in operating activities: | ||||
| Depreciation and amortization | 488,669 | 479,044 | ||
| Amortization of right-of-use assets | 122,077 | 118,829 | ||
| Non-cash loss on foreign currency translation, net | - | 555 | ||
| Provision for inventory obsolescence | - | 69,016 | ||
| Share-based compensation | 214,045 | - | ||
| Non-cash refund of R&D expenditure claims | (109,736) | (78,281) | ||
| Fair value gain on revaluation of holdback Series C preferred Stock | - | (175,738) | ||
| Non-cash other operating activities | 41,806 | 15,529 | ||
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | 163,624 | 31,027 | ||
| Inventories | 76,257 | (31,159) | ||
| Grant receivable / deferred grant income | - | 93,843 | ||
| Research and development tax incentive receivable | 149,645 | 209,591 | ||
| Deferred charges | (127,586) | - | ||
| Other current assets | 148,888 | 221,190 | ||
| Accounts and other payables | (792,051) | (630,570) | ||
| Other long-term liabilities | (135,678) | 5,091 | ||
| Operating lease liabilities | (332) | (100,151) | ||
| Net cash used in operating activities | (4,711,968) | (4,180,991) | ||
| Cash flows from Investing Activities | ||||
| Amount invested on construction in progress | (8,936) | (56,669) | ||
| Net cash used in investing activities | (8,936) | (56,669) | ||
| Cash flows from Financing Activities | ||||
| Proceeds from issuance of common stock and warrants | 686,881 | 1,342,296 | ||
| Proceeds from exercise of warrants | 7,939 | - | ||
| Proceeds from issuance of preferred stock | - | 3,036,223 | ||
| Payment of equity issuance costs | (20,626) | (592,355) | ||
| Net cash provided by financing activities | 674,194 | 3,786,164 | ||
| Effect of foreign exchange rates on cash and cash equivalents | (15,179) | 33,256 | ||
| Net decrease in cash and cash equivalents | (4,061,889) | (418,240) | ||
| Cash and cash equivalents, beginning of period | 6,304,098 | 1,537,244 | ||
| Cash and cash equivalents, end of the period | $2,242,209 | $1,119,004 | ||
| Non-cash investing and financing activities | ||||
| Conversion of preferred shares into common shares | $ | - | $57,287 | |
| Conversion of holdback Series C Preferred Stock into common stock | $ | - | $32,762 | |
| Issuance of common stock upon cashless exercise of Series F warrants | $ | - | $6,122 | |
| Amount receivable for issuance of common shares | $10,363 | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.